UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)

Journal of antibiotics, 2016-12, Vol.69 (12), p.871-878

2016

Volltextzugriff (PDF)

Innovation and Inclusion in Latin America: Strategies to Avoid the Middle Income Trap

1, 2016

Volltextzugriff (PDF)

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

The New England journal of medicine, 2019-05, Vol.380 (21), p.2020-2030

2019

Volltextzugriff (PDF)

Targeting Wall Teichoic Acid in Situ with Branched Polyethylenimine Potentiates β‑Lactam Efficacy against MRSA

ACS medicinal chemistry letters, 2017-10, Vol.8 (10), p.1083-1088

2017

Volltextzugriff (PDF)

Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial

The lancet respiratory medicine, 2020-07, Vol.8 (7), p.671-680

2020

Volltextzugriff (PDF)

LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

Annals of oncology, 2024-09, Vol.35, p.S1212-S1213

2024

Volltextzugriff (PDF)

Synthesis, in vitro, and in vivo evaluation of novel functionalized quaternary ammonium curcuminoids as potential anti-cancer agents

Bioorganic & medicinal chemistry letters, 2015-12, Vol.25 (24), p.5777-5780

2015

Volltextzugriff (PDF)

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

Annals of oncology, 2022-09, Vol.33, p.S748

2022

Volltextzugriff (PDF)

515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Annals of oncology, 2021-09, Vol.32, p.S585-S586

2021

Volltextzugriff (PDF)

Suitability of NDVI and OSAVI as estimators of green biomass and coverage in a semi-arid rangeland

Ecological indicators, 2018-11, Vol.94, p.16-21

2018

Volltextzugriff (PDF)

350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)

Annals of oncology, 2020-09, Vol.31, p.S388-S389

2020

Volltextzugriff (PDF)

Abstract P2-12-01: Dose- and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized, placebo controlled pre-surgical study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-12-01

2019

Volltextzugriff (PDF)

BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Annals of oncology, 2017-09, Vol.28, p.v76-v76

2017

Volltextzugriff (PDF)

187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial

ESMO open, 2023-05, Vol.8 (1), p.101376, Article 101376

2023

Volltextzugriff (PDF)

Abstract P3-06-03: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT trial)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P3-P3-06-03

2017

Volltextzugriff (PDF)

Multi-objective aerodynamic shape optimization of small livestock trailers

Engineering optimization, 2013-11, Vol.45 (11), p.1309-1330

2013

Volltextzugriff (PDF)

Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-04-06

2018

Volltextzugriff (PDF)

Abstract P5-21-05: Withdrawn

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-05

2018

Volltextzugriff (PDF)

Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1 -mutant ER-positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-32

2018

Volltextzugriff (PDF)

Dealing with numerical noise in CFD-based design optimization

Computers & fluids, 2014-05, Vol.94, p.84-97

2014

Volltextzugriff (PDF)

A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction

The New England journal of medicine, 1997-10, Vol.337 (16), p.1118-1123

1997

Volltextzugriff (PDF)

Inclusive Development: Escaping the Middle-Income Trap

Innovation and Inclusion in Latin America, 2016, p.33-57

2016

Volltextzugriff (PDF)

Innovation, Inclusion, and Institutions: East Asian Lessons for Latin America?

Innovation and Inclusion in Latin America, 2016, p.1-32

2016

Volltextzugriff (PDF)

1 – 25 von 626

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(380)
Mit Volltextzugriff
(404)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Life Sciences & Biomedicine
(81)
Humans
(68)
Female
(47)
Animals
(33)
Social Sciences
(33)
Chile
(31)
Adult
(29)
Male
(29)
Radiology, Nuclear Medicine & Medical Imaging
(29)
Middle Aged
(22)
Technology
(22)
Economics
(20)
Magnetic Resonance Imaging
(19)
Business & Economics
(18)
Economic Policy
(18)
Latin America
(18)
Neurosciences & Neurology
(18)
Mice
(17)
Neurosciences
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)

Innovation and Inclusion in Latin America: Strategies to Avoid the Middle Income Trap

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

Targeting Wall Teichoic Acid in Situ with Branched Polyethylenimine Potentiates β‑Lactam Efficacy against MRSA

Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial

LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

Synthesis, in vitro, and in vivo evaluation of novel functionalized quaternary ammonium curcuminoids as potential anti-cancer agents

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Suitability of NDVI and OSAVI as estimators of green biomass and coverage in a semi-arid rangeland

350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)

Abstract P2-12-01: Dose- and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized, placebo controlled pre-surgical study

BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial

Abstract P3-06-03: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT trial)

Multi-objective aerodynamic shape optimization of small livestock trailers

Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers

Abstract P5-21-05: Withdrawn

Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1 -mutant ER-positive metastatic breast cancer

Dealing with numerical noise in CFD-based design optimization

A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Inclusive Development: Escaping the Middle-Income Trap

Innovation, Inclusion, and Institutions: East Asian Lessons for Latin America?

Suchergebnisse filtern